Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Citi
Accenture
McKesson
Dow
Queensland Health
Deloitte
Harvard Business School
Fuji

Generated: September 21, 2018

DrugPatentWatch Database Preview

Ariad Company Profile

« Back to Dashboard

What is the competitive landscape for ARIAD, and what generic alternatives to ARIAD drugs are available?

ARIAD has two approved drugs.

There are six US patents protecting ARIAD drugs.

Summary for Ariad
US Patents:6
Tradenames:2
Ingredients:2
NDAs:2
Patent Litigation for Ariad: See patent lawsuits for Ariad

Drugs and US Patents for Ariad

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-001 Dec 14, 2012 RX Yes No 9,029,533 ➤ Sign Up ➤ Sign Up
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes 9,493,470 ➤ Sign Up Y Y ➤ Sign Up
Ariad ALUNBRIG brigatinib TABLET;ORAL 208772-001 Apr 28, 2017 RX Yes No ➤ Sign Up ➤ Sign Up
Ariad ICLUSIG ponatinib hydrochloride TABLET;ORAL 203469-002 Dec 14, 2012 RX Yes Yes 8,114,874 ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Non-Orange Book US Patents for Ariad

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,278,307 Monocyclic Heteroaryl compounds ➤ Sign Up
9,090,561 Acetylenic heteroaryl compounds ➤ Sign Up
8,778,942 Substituted acetylenic imidazo[1,2-A]pyrazine compounds as kinase inhibitors ➤ Sign Up
8,470,851 Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Ariad Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
327 Luxembourg ➤ Sign Up PRODUCT NAME: PONATINIB SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE
0 Finland ➤ Sign Up
13/059 Ireland ➤ Sign Up PRODUCT NAME: PONATINIB IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/839/001-004 20130701
1973545/01 Switzerland ➤ Sign Up PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: SWISSMEDIC 63097 12.02.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Dow
McKesson
QuintilesIMS
US Army
Queensland Health
Harvard Business School
Fish and Richardson
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.